Targeting neurodegenerative diseases with risuteganib as treatment therapy

Video

Glenn J. Jaffe, MD, discusses the key points of his virtual presentation on targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised, and the need for newer treatment therapies to target different pathways.


Glenn J. Jaffe, MD, professor of ophthalmology, Robert Machemer, MD, Distinguished Professor of Ophthalmology, Chief, Division of Retinal Ophthalmology at the Duke University School of Medicine, discusses the key points of his virtual presentation," Risuteganib Modulates Multiple Transcription Factors regulated by Hydroquinone in Human RPE Cells (Allegro)," including targeting neurodegenerative diseases with risuteganib, minimizing damage to the retina when compromised and the need for newer treatment therapies to target different pathways.

See more ARVO content

Newsletter

Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Recent Videos
Carl Danzig, MD, director of vitreo-retinal services at the Rand Eye Institute in Deerfield Beach, Florida, shared an update on his research in OCS-01 drops for diabetic macular edema during ARVO
Jennifer Lim, MD, FARVO, FASRS, from the University of Illinois at Chicago, discussed her ARVO presentation on sickle cell retinopathy. She highlighted improvements in retinal surgery techniques and instrumentation.
At ARVO 2025, Christine Kay, MD, shares interim results from the PRISM trial population extension cohort
ARVO 2025: Rishi Singh, MD, discusses real-world clinical outcomes in patients with DME
WIO 2024: An educator's perspective on shattering glass ceilings in ophthalmology
Hannah Chiu, MD, FRCSC, highlights some of the early benefits of an AI-operated telephone call system for postoperative patient care at WIO 2024
Retinal Inner Layer Disorganization and OCT in Uveitic Macular Edema: Insights from Dr. Amitha Domalpally
ARVO 2024: Study Reveals Faricimab's Potential for Extended Dosing in nAMD
© 2025 MJH Life Sciences

All rights reserved.